Research programme: anti-CEA fusion proteins - Cancer Research Technologies/Novozymes/UCL

Drug Profile

Research programme: anti-CEA fusion proteins - Cancer Research Technologies/Novozymes/UCL

Alternative Names: Anti-CEA scFv fusion proteins; MFE 23-albumin fusion protein; MFE-23

Latest Information Update: 01 Aug 2012

Price : $50

At a glance

  • Originator Cancer Research Technology; University College London
  • Developer Cancer Research Technology; Novozymes Delta; University College London
  • Class Albumins; Immunoglobulin fusion proteins; Immunoglobulin Fv fragments; Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 01 Aug 2012 No development reported - Early research for Solid tumours in United Kingdom (Parenteral)
  • 11 Sep 2007 Early research in Solid tumours in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top